Un altro studio (cinese) conferma la bontà del CAMRELIZUMAB (l'immunoterapico cinese) anche in relazione all'analisi costo/efficacia... https://t.co/aoEi4reQca
320 followers
2,454 followers
Cost-Effectiveness Analysis of Camrelizumab Plus Chemotherapy vs. Chemotherapy Alone as the First-Line Treatment in Patients With IIIB-IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Without EGFR and ALK Alteration from a Perspective of Health - Care …
6,533 followers
RT @FrontPharmacol: New Research: Cost-Effectiveness Analysis of Camrelizumab Plus Chemotherapy vs. Chemotherapy Alone as the First-Line Tr…
5,807 followers
New Research: Cost-Effectiveness Analysis of Camrelizumab Plus Chemotherapy vs. Chemotherapy Alone as the First-Line Treatment in Patients With IIIB–IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Without EGFR and ALK Alteration from a… https://t.co/qnp